Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Multiple Myeloma Pipeline

Sep 24, 2024

Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

Aug 05, 2024

DARZALEX FASPRO Regimen Approval: Johnson & Johnson Howling Success in Multiple Myeloma

Jul 25, 2024

BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?

Jul 24, 2024

Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes

Jul 24, 2024

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Jul 19, 2024

Multiple Myeloma: An Incurable B-cell Malignancy and A Vicious Cycle of Relapse

Mar 29, 2019

Multiple Myeloma Day

Newsletter/Whitepaper